GSK to invest in venture fund for orphan drug discovery

06/20/2013 | Reuters

GlaxoSmithKline is investing $23.5 million in Kurma Biofund II, a venture capital fund that works with a network of research institutes in Europe and focuses on rare diseases. GSK invested earlier this year in Avalon Ventures to fund up to 10 drug discovery startup companies over the next three years.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC